Income and reliability in biotech
Jul 15, 2022
2 minutes
David StevensonInvestment columnist
Over the next few months I plan to highlight several defensive funds that should escape the worst the markets have to throw at them. Let’s start with BioPharma Credit (LSE: BPCR).
With a few exceptions, the listed lending funds that have emerged over the past few years have not proved very successful. BioPharma provides credit through
You’re reading a preview, subscribe to read more.
Start your free 30 days